YOKNEAM, ISRAEL--(Marketwire - May 21, 2012) - Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today that it will host an investor meeting on Tuesday, May 22, 2012, from 10:30 am to 2:30 pm ET in New York City. The meeting will highlight Syneron's opportunity in body shaping, which includes the recent acquisition of Ultrashape Ltd. (closed on March 2, 2012). The meeting will also include presentations on other areas of Syneron's business, both in the Professional Aesthetic Device (PAD) and Emerging Business Unit (EBU) segments.
The meeting will be hosted by Syneron's management team, including:
- Shimon Eckhouse, Chairman of the Board
- Louis Scafuri, Chief Executive Officer
- Asaf Alperovitz, Chief Financial Officer
The meeting will include presentations from physician guest speakers, including:
- Christopher Inglefield, M.D., Medical Director and Owner of London Bridge Plastic Surgery & Aesthetic Clinic
- Arie Benchetrit, M.D., Cosmedica Plastic Surgery Clinic, Montreal
- Alan Gold, M.D., Plastic Surgeon, Great Neck, NY
- Zoe Diana Draelos, M.D., Dermatologist, High Point, NC
The investor meeting will be webcast live over the Internet and can be accessed through the Investor Relations section on Syneron's website at www.syneron.com. Presentation slides accompanying the presentation will also be available through the Investor Relations section of Syneron's website. Please go to the website a few minutes early in order to download the presentation and as it may be necessary to download audio software to hear the presentation. The investor meeting webcast will be archived on the Investor Relations section on Syneron's website.
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.